Diurnal Group PLC banner

Diurnal Group PLC
LSE:DNL

Watchlist Manager
Diurnal Group PLC Logo
Diurnal Group PLC
LSE:DNL
Watchlist
Price: 27.3 GBX Market Closed
Market Cap: £47.7m

Relative Value

DNL price has not been updated for more than 2 months. This may indicate that the stock has been delisted.

There is not enough data to reliably calculate the relative value of DNL.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

DNL Relative Value
Base Case
Not Available
Worst Case
Base Case
Best Case

Multiples Across Competitors

DNL Competitors Multiples
Diurnal Group PLC Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
UK
Diurnal Group PLC
LSE:DNL
46.3m GBP 9.9 -2.8 -1.6 -1.6
FR
Pharnext SCA
OTC:PNEXF
6T USD 33 643 258.8 -159 901.4 -194 171.3 -191 955.6
US
Abbvie Inc
NYSE:ABBV
409.1B USD 6.9 174.3 16.8 23.9
US
Amgen Inc
NASDAQ:AMGN
199B USD 5.4 25.8 14.8 14.8
US
Gilead Sciences Inc
NASDAQ:GILD
192.5B USD 6.6 23.7 16.2 16.2
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
124.8B USD 10.6 34 25 26.1
US
Epizyme Inc
F:EPE
94.1B EUR 2 094 -534.3 -581.8 -566.3
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
84.9B USD 5.9 18.8 14.4 16.4
AU
CSL Ltd
ASX:CSL
73.4B AUD 3.3 17 11.6 14.5
NL
argenx SE
XBRU:ARGX
42.8B EUR 14.1 33.1 56.7 58.3
US
Seagen Inc
F:SGT
39.3B EUR 20.2 -61.8 -66.7 -60.2
P/S Multiple
Revenue Growth P/S to Growth
UK
Diurnal Group PLC
LSE:DNL
Average P/S: 3 058 676
9.9
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
33 643 258.8
N/A N/A
US
Abbvie Inc
NYSE:ABBV
6.9
9%
0.8
US
Amgen Inc
NASDAQ:AMGN
5.4
2%
2.7
US
Gilead Sciences Inc
NASDAQ:GILD
6.6
4%
1.7
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
10.6
10%
1.1
US
E
Epizyme Inc
F:EPE
2 094
N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
5.9
9%
0.7
AU
CSL Ltd
ASX:CSL
3.3
5%
0.7
NL
argenx SE
XBRU:ARGX
14.1
49%
0.3
US
S
Seagen Inc
F:SGT
20.2
30%
0.7
P/E Multiple
Earnings Growth PEG
UK
Diurnal Group PLC
LSE:DNL
Average P/E: 46.7
Negative Multiple: -2.8
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -159 901.4 N/A N/A
US
Abbvie Inc
NYSE:ABBV
174.3
89%
2
US
Amgen Inc
NASDAQ:AMGN
25.8
18%
1.4
US
Gilead Sciences Inc
NASDAQ:GILD
23.7
192%
0.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
34
N/A N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -534.3 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
18.8
13%
1.4
AU
CSL Ltd
ASX:CSL
17
11%
1.5
NL
argenx SE
XBRU:ARGX
33.1
42%
0.8
US
S
Seagen Inc
F:SGT
Negative Multiple: -61.8 N/A N/A
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
UK
Diurnal Group PLC
LSE:DNL
Average EV/EBITDA: 22.2
Negative Multiple: -1.6
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -194 171.3 N/A N/A
US
Abbvie Inc
NYSE:ABBV
16.8
14%
1.2
US
Amgen Inc
NASDAQ:AMGN
14.8
10%
1.5
US
Gilead Sciences Inc
NASDAQ:GILD
16.2
7%
2.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
25
16%
1.6
US
E
Epizyme Inc
F:EPE
Negative Multiple: -581.8 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
14.4
23%
0.6
AU
CSL Ltd
ASX:CSL
11.6
8%
1.5
NL
argenx SE
XBRU:ARGX
56.7
810%
0.1
US
S
Seagen Inc
F:SGT
Negative Multiple: -66.7 N/A N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
UK
Diurnal Group PLC
LSE:DNL
Average EV/EBIT: 24.3
Negative Multiple: -1.6
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -191 955.6 N/A N/A
US
Abbvie Inc
NYSE:ABBV
23.9
30%
0.8
US
Amgen Inc
NASDAQ:AMGN
14.8
2%
7.4
US
Gilead Sciences Inc
NASDAQ:GILD
16.2
13%
1.2
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
26.1
16%
1.6
US
E
Epizyme Inc
F:EPE
Negative Multiple: -566.3 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
16.4
21%
0.8
AU
CSL Ltd
ASX:CSL
14.5
11%
1.3
NL
argenx SE
XBRU:ARGX
58.3
N/A N/A
US
S
Seagen Inc
F:SGT
Negative Multiple: -60.2 N/A N/A